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1It has been known since the early 1970s that the
extent and severity of coronary artery disease (CAD) is
a predictor of outcomes (1). Multidetector coronary
computed tomography (MD-CCT) is a useful diag-
nostic test in the assessment of CAD (2). Although it
is a minimally invasive test, MD-CCT carries atten-
dant risks. There is a risk for development of contrast-
induced nephropathy (CIN), which is significantly
See page 740
higher with intravenous contrast as compared with
intra-arterial contrast (3). CIN is associated with an
increased mortality of 15.6% at 30 days with an
odds ratio (OR) of 3.37 (95% confidence interval
[CI]: 2.58 to 4.41; p  0.001) (3). Current MD-
CCT protocols use a radiation dose similar to that
of nuclear myocardial perfusion and approximately
twice that of invasive coronary angiography (ICA)
(4). The assessment by MD-CCT of lesion stenosis
in phantom models is comparable to ICA (5);
however, coronary revascularization, either surgical
or percutaneous, is usually not performed without
prior ICA. Ideally, MD-CCT should be performed
in circumstances in which the information provided
would obviate the need for ICA and in whom
further radiation and contrast exposures would be
limited to therapeutic procedures.
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
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he presence of CAD on MD-CCT provided inde-
endent prognostic information about subsequent
eath and nonfatal myocardial infarction in a select
ohort of 529 patients who had inconclusive nonin-
asive cardiac stress tests. The presence of increasing
xtent and severity of coronary artery obstruction
iagnosed by MD-CCT was associated with an in-
rease in the combined endpoint of death and nonfatal
yocardial infarction. The hazard ratio of the com-
ined endpoint using multivariate analysis was 3.15
95%CI: 1.26 to 7.89) in patients with50% stenosis
n any coronary artery when adjusted for coronary
alcium score, age, and diabetes. Increasing degrees of
isease, when scored by the Duke CAD Index, were
lso associated with increased risk when adjusted for
he same clinical variables. Multivariate analysis did
ot include adjustment for the presence of smoking,
yslipidemia, and hypertension.
However, there are concerns regarding the appli-
ability of these findings to routine clinical practice.
hese relate to:
. Patient population. Information regarding the
indications for the initial stress testing was not
provided. This test was performed in patients at
very low risk, for example, 1 patient was 22 years
old. At the other extreme, 42 patients had typical
angina; the mean age of the patients in this study
was 57.8 years, and 61% of the population were
men. In men of this age with typical angina, the
pretest probability of significant CAD is 93% (7),
and thus noninvasive testing is likely to be of
questionable additional value. The guidelines
deem patients with high- or low-risk features on
exercise treadmill testing inappropriate for MD-
CCT (8). MD-CCT is recommended in patients
with intermediate risk on exercise treadmill test-
ing, have equivocal results after noninvasive im-
aging, or have discordant results of exercise tread-
mill testing and noninvasive imaging (8). In this
study, patients with high or low risk were included
in the initial noninvasive tests and for MD-CCT.
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7532. Treatment of comorbid conditions. Ford et al.
(9) demonstrated that the treatment of CAD risk
factors has contributed more to the reductions in
cardiovascular mortality than cardiac-specific
treatments. Appropriate and timely treatment of
comorbid conditions such as diabetes mellitus,
hypertension, and dyslipidemia together with ap-
propriate antianginal medications can be expected
to improve patient outcomes in patients with
stable angina (10,11). The authors state that
treatment of patients followed “actual clinical
practice,” however, information regarding patient
treatments and whether treatment goals were met
was not provided. Thus, it is uncertain whether
the increased events in patients with high-risk
MD-CCT findings were due solely to differences
in CAD burden or to differences in treatment as
well. Data on CIN were also not provided.
. Patient outcomes. The causes of death were
not described, and it is not known how many
patients died of cardiovascular disease; the predictors
of death were also not presented. The risk-adjusted
hazard ratio for those with severe stenosis was 13.29
(95% CI: 2.47 to 71.32). The event rate in the 104
patients with severe stenosis who had 70% ob-
struction of CAD was not provided. It is also not
known whether the findings on MD-CCT altered
the management and treatment of the patients.
Knowing that death was not likely related to cardio-conventional angiography and com- et al. ACCF/SCtreatment that ensued after MD-CCT may have
been beneficial. Sixty-eight patients underwent re-
vascularization; did these patients have ICA prior to
the procedure? The ICA would have added to
further radiation and contrast exposure. It is prudent
to be judicious in the use of tests that cause signifi-
cant radiation exposure. Radiation dosage is lower in
currently available MD-CCT.
The authors presented prognostic data that are inter-
sting and useful (6). The study group was “homoge-
ous,” and partly by design, was aligned with current
ppropriateness guidelines. However, given the consid-
rations outlined in the preceding text, there are limita-
ions to this study. The authors provided no information
hat the findings on MD-CCT in patients with appro-
riate indications for noninvasive testing andwith appro-
riate, but inconclusive, tests resulted in any benefit to
atient care by improving treatment(s) and quality of life
nd/or by reducing the incidence of subsequent myocar-
ial infarction or deaths from cardiovascular causes.
uture studies need to be more focused and should
ocument whether better outcomes occur because of the
esult(s) of the test. At that time, the risks of the
rocedure should be balanced against the benefits.
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